-
(S)-(+)-Dimethindene maleate Protocol Guide
2026-09-09
This guide explains how to use (S)-(+)-Dimethindene maleate as a research antagonist for M2 muscarinic and H1 histamine receptor workflows when concentration-response and selectivity conditions must be established experimentally. It supports controlled in vitro or ex vivo pharmacology studies, but it should not be used for diagnosis, treatment, or as evidence for clinical efficacy.
-
Caffeine Workflows for Cancer and Metabolism
2026-09-08
Build reproducible Caffeine experiments spanning sarcoma cell line inhibition, valproic acid combination studies, and energy-balance research. This guide connects formulation, assay controls, and translational interpretation while keeping caffeine evidence distinct from emerging ALDH2 cardiovascular research.
-
SIRT1/2 Inhibitor IV: Mechanism-to-Assay Guide
2026-09-08
SIRT1/2 Inhibitor IV, also known as cambinol, is a dual SIRT1/SIRT2 tool for connecting deacetylase activity with p53 acetylation, tumor biology, hypoxia, and lactate-regulated signaling. This guide emphasizes causal assay design and the limits of interpreting dual-target pharmacology in cancer and CNS models.
-
Toremifene for Breast Cancer: 20 Years of Evidence
2026-09-07
This review synthesizes two decades of clinical and pharmacologic evidence for toremifene, positioning it as an effective endocrine option for selected postmenopausal patients with estrogen receptor-positive breast cancer. Its main contribution is a clinically useful comparison with tamoxifen and aromatase inhibitors, emphasizing distinct metabolism, tissue-selective effects, and the limits of claims about safety superiority.
-
TBXA2R–ERM Signaling in TNBC Metastasis
2026-09-05
The reference study identifies TBXA2R as a GPCR that activates ERM proteins through Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK, thereby promoting triple-negative breast cancer motility, invasion, and metastatic colonization. Its main contribution is a mechanistic link between receptor signaling and the membrane–cytoskeleton machinery that governs metastatic behavior, while also providing a framework for testing related GPCR pathways without assuming they are interchangeable.
-
Shh–Fgf Signaling in Guinea Pig Penile Development
2026-09-05
Wang and Zheng identify species-specific differences in Sonic hedgehog and Fgf10/Fgfr2 expression that help explain why guinea pigs form an open urethral groove whereas mice primarily canalize a urethral plate. By combining comparative expression profiling with organ culture perturbation, the study provides a useful framework for evaluating how developmental signaling and model selection shape investigations of penile morphogenesis.
-
Berberrubine chloride: Applied Research Workflows
2026-09-04
Berberrubine chloride supports mechanism-led workflows spanning colorectal cancer, NSCLC chemosensitivity, urate biology, and inflammation research. Its DMSO handling profile and distinct IMPDH2, TrxR, and CYP2D6-related findings make it useful for connecting phenotypic assays with target and metabolism studies.
-
VE-821: Selective ATR Kinase Inhibitor
2026-09-04
VE-821 is an ATP-competitive ATR kinase inhibitor with reported nanomolar biochemical potency and selectivity over several related kinases. It is used in DNA damage response inhibitor studies, including checkpoint signaling, radiosensitization assays, and chemotherapy sensitization experiments.
-
MEDUSA Reveals Hidden Death Mechanisms
2026-09-03
Honeywell and colleagues developed MEDUSA, a time-resolved modeling framework that separates drug-induced changes in cell growth from changes in cell death during functional genomic screens. Applied to DNA damage responses, the method revealed that p53 loss redirects cells from apoptosis toward a nonapoptotic, respiration-dependent death program, offering a more precise route to identify genetic determinants of drug lethality.
-
Measuring Drug Arrest and Death in Cancer Cells
2026-09-03
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated readouts capture different mixtures of proliferative arrest and cell death. The framework supports more informative in vitro drug-response studies by adding time-resolved, mechanistically aligned measurements rather than treating a single viability value as a direct measure of cytotoxicity.
-
Sulfo-NHS-LC-Biotin: Practical Labeling Guide
2026-09-02
Sulfo-NHS-LC-Biotin provides water-compatible, irreversible biotin labeling of primary amines on proteins, peptides, and intact cell surfaces. It is suited to stable surface labeling, streptavidin capture, and biotin-avidin detection, but not to reversible or intracellular labeling workflows.
-
MRT68921 ULK1 Kinase Inhibitor Workflow
2026-09-02
MRT68921 provides a practical way to suppress ULK1/2-dependent autophagy initiation while separating ULK signaling from the broader energy-stress response. This guide combines dose-finding, ATG13 phosphorylation blockade, LC3 flux measurement, genetic controls, and troubleshooting for reproducible cell-based assays.
-
Tropifexor (LJN452) FXR Assay Workflows
2026-09-01
Build more informative FXR experiments by pairing Tropifexor with reporter, barrier, and fibrosis readouts rather than relying on a single endpoint. This workflow guide shows how to use LJN452 in intestinal epithelial barrier function research, metabolic disease research, and liver disease models while separating receptor activity from cytotoxicity and pathway overlap.
-
GI 254023X: Precision in ADAM10 Translation
2026-08-31
GI 254023X offers a selective way to interrogate ADAM10 sheddase biology across Notch1 signaling, Jurkat-cell responses, endothelial barrier protection, and toxin-associated vascular injury. This thought-leadership perspective connects mechanistic selectivity with translational study design, emphasizing exposure windows, orthogonal validation, and the limits of preclinical interpretation.
-
Mouse Neutrophil Cell Isolation Kit for Immunotherapy
2026-08-31
The Mouse Neutrophil Cell Isolation Kit supports high-purity, low-perturbation neutrophil preparation for immunology and cancer research. This guide connects negative selection with assay design, tissue-specific interpretation, and emerging neutrophil-targeted mRNA nanovaccines.